Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection.

Machine translation Machine translation
类别 Primary study
期刊The American journal of gastroenterology
Year 2004
連結 Pubmed
目标：我们评估了长期的积极性肝硬化失代偿期患者HBeAg-negative/HBV-DNA拉米夫定单一疗法的疗效。方法：我们分析了临床课程，并在连续30肝硬化患者拉米夫定治疗结果，并与30个未经处理的历史乙肝e抗原阴性的年龄和性别匹配的对照。结果：临床显着改善，定义为至少有两点是儿童，Pugh评分减少在30（76.6％）相对于对照组（p，30例患者无治疗的患者23观察<0.0001）结束平均随访20.6 + / - 12.1（+ / -标清）个月。有10人死亡和24治疗组在对照组（p = 0.07）。肝有关的死亡发生在八五年后不久，病人的生化突破性发展。与患者有临床改善优于无改善（P = 0.04）或谁开发生化突破由于YMDD变异性（P = 0.001患者的存活率）。结论：拉米夫定显着提高e抗原阴性的肝硬化肝功能失代偿。然而，由于生化突破YMDD变异发展是与致命的结果。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 8a9a92956b9e79245e8c8e50fb0eda9368dac954
First added on: Jun 08, 2011
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use